Show simple item record

Authordc.contributor.authorHetz Flores, Claudio 
Authordc.contributor.authorAxten, Jeffrey M. 
Authordc.contributor.authorPatterson, John B. 
Cita de ítemdc.identifier.citationNature Chemical Biology, Volumen 15, Issue 8, 2019, Pages 764-775
Abstractdc.description.abstract© 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.Accumulation of unfolded proteins at the endoplasmic reticulum (ER) is a salient attribute of many human diseases including obesity, liver disorders, cancer, diabetes and neurodegeneration. To restore ER proteostasis, cells activate the unfolded protein response (UPR), a signaling pathway that imposes adaptive programs or triggers apoptosis of damaged cells. The UPR is critical to sustain the normal function of specialized secretory cells (i.e., pancreatic β cells and B lymphocytes) and to control the production of lipids and cholesterol in the liver. In the context of disease, adaptive UPR responses have been linked to the growth of solid tumors, whereas chronic ER stress contributes to cell dysfunction in brain diseases, metabolic syndromes, among other conditions. Here we discuss recent developments in the design and optimization of novel compounds to manipulate UPR signaling and their efficacy in various
Publisherdc.publisherNature Publishing Group
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.uri
Sourcedc.sourceNature Chemical Biology
Keywordsdc.subjectMolecular Biology
Keywordsdc.subjectCell Biology
Títulodc.titlePharmacological targeting of the unfolded protein response for disease intervention
Document typedc.typeArtículo de revista
Indexationuchile.indexArtículo de publicación SCOPUS

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile